Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Document and Entity Information

v3.22.2
Document and Entity Information
 12 Months Ended
Mar. 31, 2022
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Mar. 31, 2022
Document Fiscal Year Focus 2022
Document Fiscal Period Focus FY
Entity Registrant Name Virax Biolabs Group Limited
Entity Central Index Key 0001885827
Entity Current Reporting Status Yes
Entity Voluntary Filers No
Entity Interactive Data Current Yes
Current Fiscal Year End Date --03-31
Entity Filer Category Non-accelerated Filer
Entity Well-known Seasoned Issuer No
Entity Common Stock, Shares Outstanding 815,746,293
Entity Shell Company false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-41440
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 30 Broadwick Street
Entity Address, City or Town London
Entity Address, Postal Zip Code W1F 8LX
Entity Address, Country GB
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Registration Statement false
Document Accounting Standard International Financial Reporting Standards
ICFR Auditor Attestation Flag false
Auditor Name BF Borgers CPA PC
Auditor Firm ID 5041
Auditor Location Lakewood, CO
Trading Symbol VRAX
Title of 12(b) Security Ordinary Shares, par value $.0001 per share
Security Exchange Name NASDAQ
Business Contact  
Document Information [Line Items]  
Entity Address, Address Line One 30 Broadwick Street
Entity Address, City or Town London
Entity Address, Postal Zip Code W1F 8LX
Entity Address, Country GB
City Area Code +44 020
Local Phone Number 7788 7414
Contact Personnel Name James Foster
Contact Personnel Email Address jf@viraxbiolabs.com